Phio Pharmaceuticals Corp. yakazivisa nhasi kuti yakavhura kunyoresa kwevarwere muPhase 1b yekiriniki yekuyedza yePH-762 yekurapa melanoma yakakura.
"Tinofara kufambisira mberi muyedzo wedu wekiriniki wekutanga-mu-munhu wechirongwa chedu chinotungamira, PH-762, chekurapa varwere vane melanoma. Kutanga kwechidzidzo chekiriniki iyi kunoratidza chiitiko chakakosha chePhio uye yedu INTASYL yekurapa kwepuratifomu, "akadaro Dr. Gerrit Dispersyn, Mutungamiriri uye CEO wePhio. "Ichi chidzidzo chakakosha kune varwere vane melanoma yepamusoro zvakare, sezvo parizvino, hapana nzira dzekurapa neoadjuvant dzakatenderwa varwere ava. Pamusoro pezvo, chirongwa chekiriniki chePH-762 chekurapa melanoma chinotsigirwa neseti yakasimba yedata rekiriniki rakagadzirwa mumakore akati wandei apfuura. Idzi data dzinoratidza kuti kurapwa kwepanzvimbo kwePH-762 hakungodziviriri kukura kwebundu remunharaunda, asi zvakare kunopa mhedzisiro kana systemic immune immune mumamota asina kurapwa.
Iyo Phase 1b yekudzidza, iyo iri kuitwa paGustave Roussy Institute, imwe yenzvimbo huru dzegomarara muEurope, ichaongorora kuchengetedzwa, kushivirira, pharmacokinetics uye anti-tumor chiitiko chePH-762 mune neoadjuvant kurongeka muzvidzidzo zvine melanoma yepamusoro. . Chidzidzo chekiriniki chicharatidza kuwedzera kwedosi yePH-762 monotherapy uye yakagadzirirwa kubvumidza kuongororwa kunofambiswa nedatha kweiyo yakakurudzirwa Phase 2 dosi. Iyi ndiyo yekutanga kuyedzwa kwekiriniki nePH-762.
PH-762, inoita kuti masero edziviriro akwanise kuziva nekuuraya maseru egomarara. Inozviita nekudzikisa kutaura kwePD-1, chinangwa chekiriniki chakasimbiswa che immunotherapy. PD-1 inoratidzwa neT masero uye inovadzivirira kubva pakuuraya masero egomarara. Kana PH-762 ichidzikisa PD-1 kutaura, "mabhureki" ari pa immune system anoburitswa uye anomisa masero eT kuuraya masero egomarara. PH-762 iri kugadzirwa seyakamira yega mushonga kurapa nekutonga kwenzvimbo kune bundu. Pamusoro pezvo, iri kuvandudzwa zvakare sechinhu chakakosha che cellular immunotherapy, kunyanya kuvandudza bundu cell kuuraya kugona kwekugamuchira inotamisa bundu infiltrating lymphocyte (TIL) kurapwa.
ZVOKUBVA MUNYAYA INO:
- The Phase 1b study, which is being conducted at the Gustave Roussy Institute, one of the largest cancer centers in Europe, will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of PH-762 in a neoadjuvant setting in subjects with advanced melanoma.
- The clinical study will feature a dose escalation of PH-762 monotherapy and is designed to allow for a data driven evaluation of the recommended Phase 2 dose.
- In addition, the clinical program for PH-762 to treat melanoma is supported by a robust set of preclinical data generated over the past several years.
